Paper25757
Labetalol: a review of its pharmacology and therapeutic use in hypertension.
Brogden RN and 3 others. Drugs, 1978. Cited by 104 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Labetalol: a review of its pharmacology and therapeutic use in hypertension. Papers, record 25757. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25757
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Ethanolamines | Major topic |
| Hypertension | Major topic |
| Labetalol | Major topic |
| Adrenal Gland Neoplasms | |
| Adrenergic alpha-Antagonists | |
| Adrenergic beta-Antagonists | |
| Angiotensin II | |
| Half-Life | |
| Hemodynamics | |
| Humans | |
| Pheochromocytoma | |
| Renin | |
| Respiration |
Source PubMed
References58
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 12,115 | Antihypertensive effect of labetalol, a new alpha- and beta-adrenergic blocking agent. | Int J Clin Pharmacol Biopharm | 1976 | https://conductscience.org/library/papers/12115 | PubMed |
| 2 | 10,948 | A review of the animal pharmacology of labetalol, a combined alpha- and beta-adrenoceptor-blocking drug. | Br J Clin Pharmacol | 1976 | https://conductscience.org/library/papers/10948 | PubMed |
| 3 | 791,330 | Experience with labetalol in hypertension. | Br J Clin Pharmacol | 1976 | https://conductscience.org/library/papers/791330 | PubMed |
| 4 | 990,158 | Treatment of phaeochromocytoma and of clonidine withdrawal hypertension with labetalol. | Br J Clin Pharmacol | 1976 | https://conductscience.org/library/papers/990158 | PubMed |
| 5 | 990,159 | Cardiovascular effects of labetalol during halothane anaesthesia. | Br J Clin Pharmacol | 1976 | https://conductscience.org/library/papers/990159 | PubMed |
| 6 | 236,806 | Comparison of intravenous AH 5158 (ibidomide) and propranolol in asthma. | Br Med J | 1975 | https://conductscience.org/library/papers/236806 | PubMed |
| 7 | 791,333 | Effect of blood pressure angiotensin II and aldosterone concentrations during treatment of severe hypertension with intravenous labetalol: comparison with propranolol. | Br J Clin Pharmacol | 1976 | https://conductscience.org/library/papers/791333 | PubMed |
| 8 | 62,582 | Labetalol in long-term treatment of hypertension. | Br J Clin Pharmacol | 1976 | https://conductscience.org/library/papers/62582 | PubMed |
| 9 | 843,418 | Comparison of the effects of labetalol and propranolol in healthy men at rest and during exercise. | Br J Clin Pharmacol | 1977 | https://conductscience.org/library/papers/843418 | PubMed |
| 10 | 791,332 | Comparative anti-hypertensive effects of labetalol and the combination of oxprenolol and phentolamine. | Br J Clin Pharmacol | 1976 | https://conductscience.org/library/papers/791332 | PubMed |
| 11 | 851,058 | Acute hemodynamic effects of an alpha- and beta-receptor blocking agent (AH 5158) on the systemic and pulmonary circulation at rest and during exercise in hypertensive patients. | Am Heart J | 1977 | https://conductscience.org/library/papers/851058 | PubMed |
| 12 | 69,898 | Scalp tingling in patients on labetalol. | Lancet | 1977 | https://conductscience.org/library/papers/69898 | PubMed |
| 13 | 14,627 | Labetalol (AH5158), a competitive alpha- and beta-receptor blocking drug, in the management of hypertension. | Aust N Z J Med | 1976 | https://conductscience.org/library/papers/14627 | PubMed |
| 14 | 4,184 | Proceedings: The effects of AH 5158 on the overflow of transmitter and the uptake of (3H)-(--)-noradrenaline in the cat spleen. | Br J Pharmacol | 1976 | https://conductscience.org/library/papers/4184 | PubMed |
| 15 | 4,152,254 | The effects of a new alpha- and beta-adrenoceptor antagonist (AH5158) upon the general and coronary haemodynamics of intact dogs. | Br J Pharmacol | 1973 | https://conductscience.org/library/papers/4152254 | PubMed |
| 16 | 4,404,413 | Pharmacology of AH 5158; a drug which blocks both - and -adrenoceptors. | Br J Pharmacol | 1972 | https://conductscience.org/library/papers/4404413 | PubMed |
| 17 | 10,953 | Intravenous labetalol in hypertensive patients treated with beta-adrenoreceptor-blocking drugs. | Br J Clin Pharmacol | 1976 | https://conductscience.org/library/papers/10953 | PubMed |
| 18 | 238,705 | Combined alpha- and beta-adrenoceptor blocking drug AH 5158: further studies on alpha-adrenoceptor blockade in anaesthetized animals. | Br J Pharmacol | 1975 | https://conductscience.org/library/papers/238705 | PubMed |
| 19 | 901,712 | Rate of onset of hypotensive response with oral labetalol [proceedings]. | Br J Clin Pharmacol | 1977 | https://conductscience.org/library/papers/901712 | PubMed |
| 20 | 22,454,938 | The effects of oral AH 5158, a combined α and β-adrenoceptor antagonist, in healthy volunteers. | Br J Clin Pharmacol | 1974 | https://conductscience.org/library/papers/22454938 | PubMed |
Cited by26
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 104 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 36,365,181 | Development and Evaluation of a Physiologically Based Pharmacokinetic Model of Labetalol in Healthy and Diseased Populations. | Pharmaceutics | 2022 | https://conductscience.org/library/papers/36365181 | PubMed |
| 7,426,837 | Direct vasodilatation by labetalol in anaesthetized dogs. | Br J Pharmacol | 1980 | https://conductscience.org/library/papers/7426837 | PubMed |
| 7,374,093 | Effects of chronic alpha and beta adrenoceptor blockade with labetalol on plasma catecholamines and renal function in hypertension. | Klin Wochenschr | 1980 | https://conductscience.org/library/papers/7374093 | PubMed |
| 7,295,465 | Blood pressure, body fluid volumes and glomerular filtration rate during treatment with labetalol in essential hypertension. | Br J Clin Pharmacol | 1981 | https://conductscience.org/library/papers/7295465 | PubMed |
| 7,180,007 | The management of the patient with catecholamine excess. | World J Surg | 1982 | https://conductscience.org/library/papers/7180007 | PubMed |
| 7,093,098 | Labetalol: the nineteen-eighties. | Br J Clin Pharmacol | 1982 | https://conductscience.org/library/papers/7093098 | PubMed |
| 6,980,012 | Review of long-term treatment with labetalol. | Br J Clin Pharmacol | 1982 | https://conductscience.org/library/papers/6980012 | PubMed |
| 6,310,204 | Sympathetic nervous activity and the pressor effect of noradrenaline under chronic alpha-beta-adrenoceptor blockade with labetalol in hypertension. | Klin Wochenschr | 1983 | https://conductscience.org/library/papers/6310204 | PubMed |
| 6,151,890 | Pharmacology of combined alpha-beta-blockade. II. Haemodynamic effects of labetalol. | Drugs | 1984 | https://conductscience.org/library/papers/6151890 | PubMed |
| 6,124,264 | Labetalol in essential hypertension. | Br J Clin Pharmacol | 1982 | https://conductscience.org/library/papers/6124264 | PubMed |
| 6,122,340 | Improved deep controlled hypotension in aneurysmal surgery. | Acta Neurochir (Wien) | 1982 | https://conductscience.org/library/papers/6122340 | PubMed |
| 6,103,797 | Antinuclear antibodies and cardiovascular drugs. | Drugs | 1980 | https://conductscience.org/library/papers/6103797 | PubMed |
| 3,154,919 | Role of vasodilation in the antihypertensive and antianginal effects of labetalol: implications for therapy of combined hypertension and angina. | Cardiovasc Drugs Ther | 1988 | https://conductscience.org/library/papers/3154919 | PubMed |
| 2,908,732 | Properties of labetalol, a combined alpha- and beta-blocking agent, relevant to the treatment of myocardial ischemia. | Cardiovasc Drugs Ther | 1988 | https://conductscience.org/library/papers/2908732 | PubMed |
| 2,872,908 | Effect of labetalol on limb haemodynamics in patients following coronary artery bypass graft surgery. | Br J Clin Pharmacol | 1986 | https://conductscience.org/library/papers/2872908 | PubMed |
| 2,770,185 | [Effectiveness and hemodynamic mechanism of action of blood pressure lowering by intravenous labetalol in patients with a critical increase in blood pressure]. | Klin Wochenschr | 1989 | https://conductscience.org/library/papers/2770185 | PubMed |
| 2,663,413 | Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease. | Drugs | 1989 | https://conductscience.org/library/papers/2663413 | PubMed |
| 1,678,963 | Acute and chronic hemodynamic effects of drugs with different actions on adrenergic receptors: a comparison between alpha blockers and different types of beta blockers with and without vasodilating effect. | Cardiovasc Drugs Ther | 1991 | https://conductscience.org/library/papers/1678963 | PubMed |
| 732,886 | Release of noradrenaline by labetalol in the rat anococcygeus muscle. | Naunyn Schmiedebergs Arch Pharmacol | 1978 | https://conductscience.org/library/papers/732886 | PubMed |
| 583,322 | Comparative haemodynamic effects of labetalol, timolol, prazosin and the combination of tolamolol and prazosin. | Br J Clin Pharmacol | 1979 | https://conductscience.org/library/papers/583322 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/25757
GET https://conductscience.org/api/papers/v1/25757/references?page=2